IL132848A - Preparation for the treatment of fetal cirrhosis - Google Patents

Preparation for the treatment of fetal cirrhosis

Info

Publication number
IL132848A
IL132848A IL13284898A IL13284898A IL132848A IL 132848 A IL132848 A IL 132848A IL 13284898 A IL13284898 A IL 13284898A IL 13284898 A IL13284898 A IL 13284898A IL 132848 A IL132848 A IL 132848A
Authority
IL
Israel
Prior art keywords
halofuginone
group
collagen
liver
hepatic
Prior art date
Application number
IL13284898A
Other languages
English (en)
Hebrew (he)
Other versions
IL132848A0 (en
Original Assignee
Israel State
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25338371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Israel State, Hadasit Med Res Service filed Critical Israel State
Publication of IL132848A0 publication Critical patent/IL132848A0/xx
Publication of IL132848A publication Critical patent/IL132848A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13284898A 1997-05-23 1998-05-22 Preparation for the treatment of fetal cirrhosis IL132848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86238297A 1997-05-23 1997-05-23
PCT/US1998/010505 WO1998052514A2 (fr) 1997-05-23 1998-05-22 Traitement de la cirrhose hepatique

Publications (2)

Publication Number Publication Date
IL132848A0 IL132848A0 (en) 2001-03-19
IL132848A true IL132848A (en) 2004-08-31

Family

ID=25338371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13284898A IL132848A (en) 1997-05-23 1998-05-22 Preparation for the treatment of fetal cirrhosis

Country Status (8)

Country Link
EP (1) EP1014988A2 (fr)
JP (1) JP2002515905A (fr)
KR (1) KR100540537B1 (fr)
CN (1) CN1160073C (fr)
AU (1) AU748754B2 (fr)
CA (1) CA2290502C (fr)
IL (1) IL132848A (fr)
WO (1) WO1998052514A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278579A1 (en) * 2002-10-31 2004-05-25 Collgard Biopharmaceuticals Ltd Quinazolinone compositions for regulation of gene expression related to pathological processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
CA2113229C (fr) * 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes

Also Published As

Publication number Publication date
KR20010012838A (ko) 2001-02-26
CN1160073C (zh) 2004-08-04
AU748754B2 (en) 2002-06-13
EP1014988A2 (fr) 2000-07-05
KR100540537B1 (ko) 2006-01-10
WO1998052514A2 (fr) 1998-11-26
WO1998052514A3 (fr) 1999-08-19
AU7692298A (en) 1998-12-11
JP2002515905A (ja) 2002-05-28
CN1265034A (zh) 2000-08-30
CA2290502A1 (fr) 1998-11-26
CA2290502C (fr) 2007-08-28
IL132848A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
IL131348A (en) Composition for treatment and prevention of adhesions
US20060194822A1 (en) Treatment for renal fibrosis
WO2000064470A1 (fr) Formulation pharmaceutique comportant un inhibiteur de thrombine de faible poids moleculaire et son promedicament
US6562829B1 (en) Treatment of hepatic cirrhosis
CA2568436A1 (fr) Therapie combinee impliquant un antagoniste de recepteur d'adenosine a1 et un inhibiteur d'aldosterone
JP2002509540A (ja) アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物
JP2003503457A (ja) 心臓血管合併症の治療用薬剤の製造におけるアンギオテンシンｉｉ１型受容体アンタゴニストの使用
CA2290502C (fr) Traitement de la cirrhose hepatique
US5872124A (en) Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
AU2002309211A1 (en) Treatment of renal fibrosis
US7439077B2 (en) Coumarin analog compounds for safer anticoagulant treatment
AU739148B2 (en) Treatment of skin disorders
US20140288102A1 (en) Prevention of recurrences of urethral strictures following conventional therapy
AU737094B2 (en) Treatment for pulmonary fibrosis
KR20200026975A (ko) 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
US20220378754A1 (en) Compositions and methods for treating slow-flow vascular malformations
WO2005055997A1 (fr) Composition medicinale pour traiter et pour prevenir une maladie inflammatoire
AU2008201290B2 (en) Therapeutic treatment
US20040068006A1 (en) Method for preventing acute renal failure
Whayne Women and cardiovascular disease—Prevention of heart disease
WO2001097798A1 (fr) Procede servant a prevenir ou a reduire des evenements cardio-vasculaires induits par intervention coronarienne
WO2002056941A2 (fr) Methode de traitement de l'acrosyndrome
AU2014262206A1 (en) Prevention of recurrence of urethral stricture after a conventional treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired